TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01461499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: The patient will start taking one a daily 150 mg/day of aliskiren. In case blood pressure doesn't reach the target (SBP/DBP \< 130/80 mmHg), higher dose of aliskiren will be given.In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: any angiotensin receptor blockers
Description: The patient will start taking one a standard dose of an ARB in Japan. In case blood pressure doesn't reach the target (SBP/DBP \< 130/80 mmHg), higher dose of the ARB will be given. In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (DRI, another ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
Study: NCT03051464

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complete responders and Non-complete responders
Description: Patients that are complete responders will not have surgery. Patients that are non-complete responders will have surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complete responders and Non-complete responders
Description: Patients that are complete responders will not have surgery. Patients that are non-complete responders will have surgery.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation + EBRT Boost
Description: 45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation + HDRBT Boost
Description: 45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions
Study: NCT05434793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RJ-LASER, LASERPEN®; Reimers & Janssen, Germany
Description: The device was frequently used in laser acupuncture on the superficial skin of the acupuncture point Tsu San Li (St-36).
Study: NCT03461562

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Aerobic exercise wil be held for 40 minutes. Dynamic exercises will be accompanied by physiotherapist on the vibration platform for 15 minutes. Same excercises will be held stable platform (when the devices turned off) by control group for 15 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercise wil be held for 40 minutes. Dynamic exercises will be accompanied by physiotherapist on the vibration platform for 15 minutes. Same excercises will be held stable platform (when the devices turned off) by control group for 15 minutes.
Study: NCT02181946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Study: NCT02524236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox injection in the prostate
Description: transrectal access of prostatic injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox injection in the prostate
Description: transrectal access of prostatic injection
Study: NCT01520649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSI-189 Phosphate
Description: The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: microcrystalline cellulose capsules
Description: The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
Study: NCT04328545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS on DLPFC
Description: Participants will receive anodal tDCS on the left DLPFC for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal tDCS on M1
Description: Participants will receive anodal tDCS on the left M1 for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Participants will receive sham tDCS. The anode will be placed on the left DLPFC and the cathode on the over the right supra orbital area. The electrodes are 25cm², There will be a ram up and down of 30 seconds each, after the ramp up the current will be turned off.
Study: NCT02342782

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yttrium Y 90 Basiliximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo AHCT
Study: NCT01747070

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tDCS sham and EAC
Description: For the sham tDCS we will use the same apparatus in the same location, but the current is stopped after 30 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS and EAC
Description: For the acupuncture we will use needles with guide tubes that are 40 mm in length and 0.25 mm in diameter. The needling will be applied using an electro acupuncture device in the dermatomes, myotome, or sclerotome corresponding to the nerve roots involved in the knee (L1, L2, L3, L4, L5, S1, and S2). All patients received one 30min session using a frequency of 2 Hz.
Study: NCT02342782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT05276336

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency turbinate reduction
Description: Before the radiofrequency turbinate reduction procedure, local anaesthesia will be given by applying a cotton tamponade soaked in lidocaine adrenaline 1:5000 titration and added with xylocaine gel for 10 minutes in both nostrils. Then, a mixture of 1 mL of lidocaine 2% and 2 mL of sodium chloride 0,9% will be infiltrated to both nostrils using 3 mL and 1 mL needles until the inferior turbinates are pale. The radiofrequency probe (made by Sutter, both in monopolar and bipolar modes) will be inserted to the distal inferior turbinate until the black line from the probe is inside the inferior turbinate (approximately 10-12 mm). The procedure will be done for 10 seconds and the insertion of the probe can be done in 2-3 sites. After this, subjects from this group will be treated with pharmacology treatment using intranasal steroid and AH-1 according to ARIA WHO guideline 2008, similar to the pharmacology treatment received by the control group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacology treatment
Description: Subjects will be treated with intranasal steroid and AH-1 according to ARIA WHO guideline 2008. Fluticasone furoate will be given twice a day with two sprays (100 µg) for each nostril for 2 weeks, then continue for once a day with two sprays (100 µg). Antihistamine H-1 is given 10 mg, once a day. Pharmacology treatment is given for 4 weeks, then intranasal steroid will be continued for another 4 weeks.
Study: NCT00273624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 10 mg Olanzapin concurrent to antidepressive medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00574834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Ramipril 20 mg once daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ-hydrochlorothiazide
Description: HCTZ 25 mg once daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril+HCTZ
Description: Ramipril 20 mg and HCTZ 25 mg, both once daily for 6 months
Study: NCT05276336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacology treatment
Description: Subjects will be treated with intranasal steroid and AH-1 according to ARIA WHO guideline 2008. Fluticasone furoate will be given twice a day with two sprays (100 µg) for each nostril for 2 weeks, then continue for once a day with two sprays (100 µg). Antihistamine H-1 is given 10 mg, once a day. Pharmacology treatment is given for 4 weeks, then intranasal steroid will be continued for another 4 weeks.
Study: NCT04346186

Intervention type: DIAGNOSTIC_TEST
Intervention: IgM and IgG diagnostic kits to SARS-CoV-2
Description: Diagnostic kits for IgM/IgG antibodies to SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: IgM and IgG diagnostic kits to SARS-CoV-2
Description: Diagnostic kits for IgM/IgG antibodies to SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Elisa-test for IgM and IgG to SARS-CoV-2
Description: Elisa-test for IgM and IgG to SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Elisa-test for IgM and IgG to SARS-CoV-2
Description: Elisa-test for IgM and IgG to SARS-CoV-2
Study: NCT01453452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral dietary intervention
Description: Reduce caloric intake by 500 kcal/day, increase fruit and vegetable intake to 5 or more servings per day, and limit daily calories from fat to be \< 30%. Diet will be measured using 3 repeated 24-hr diet recalls. Participants will receive information on the recommended dietary modifications via mailed materials and telephone counseling sessions.
Study: NCT00867256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Large Diameter Metal on Metal
Study: NCT00017472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: apolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02121002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium Topical Gel, 1%
Description: Opaque, white gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voltaren Topical Gel, 1%
Description: Opaque, white gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Diclofenac Sodium Topical Gel
Description: Opaque, white gel
Study: NCT00275392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Description: vestibular adaptation and substitution exercises

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo vestibular exercises
Study: NCT04553458

Intervention type: DEVICE
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation of the tumour

Intervention type: DEVICE
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation of the tumour

Intervention type: DRUG
Intervention: Trance-arterial chemoembolization
Description: Trance-arterial chemotherapy

Intervention type: DRUG
Intervention: Trance-arterial chemoembolization
Description: Trance-arterial chemotherapy

Intervention type: PROCEDURE
Intervention: Liver resection
Description: non-anatomical or anatomical liver resection

Intervention type: COMBINATION_PRODUCT
Intervention: Combined radiofrequency ablation + percutaneous ethanol injection
Description: combined therapy

Intervention type: COMBINATION_PRODUCT
Intervention: Combined radiofrequency ablation + percutaneous ethanol injection
Description: combined therapy

Intervention type: DRUG
Intervention: Percutaneous ethanol injection
Description: Percutaneous ethanol injection of HCC

Intervention type: DRUG
Intervention: Percutaneous ethanol injection
Description: Percutaneous ethanol injection of HCC

Intervention type: DRUG
Intervention: Systemic chemotherapy
Description: Systemic chemotherapy

Intervention type: DRUG
Intervention: Sorafenib
Description: Sorafenib

Intervention type: DIETARY_SUPPLEMENT
Intervention: Viscum
Description: Viscum for HCC
Study: NCT00758680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1006
Description: MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1006
Description: MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1006
Description: MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1006
Description: MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1006
Description: MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1006
Description: MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1006
Description: MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1006
Description: MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo comparator
Description: Dose-matched MK-1006 placebo capsules (1 mg, 10 mg and 20 mg) administered orally over a multiple dosing period.
Study: NCT03393806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3772847
Description: GSK3772847 will be available as 100 mg/vial, white to yellow, uniform lyophilized cake in a 5 milliliter (mL) clear glass vial with closure sealed by red metal and yellow overseal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially sourced sterile normal saline will be provided as Placebo
Study: NCT02686645

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota
Description: The fecal microbiota will be by retention enema administered through a rectal tube.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vancomycin
Description: All subjects will be pre-treated with vancomycin 125 mg po qid X 7 days prior to the fecal microbiota.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: The subject will take 4 mg of loperamide after the morning bowel prep (approximately 1 hour prior to the procedure) and 2 mg again after the procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole
Description: If unable to tolerate vancomycin, then it will be substituted with metronidazole 500 mg po tid X 7 days prior to the fecal microbiota.
Study: NCT02567643

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Study: NCT05332028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine
Description: Block applications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: Block applications

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 22 gauge 100 mm needle
Description: Block applications

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22 gauge 100 mm needle
Description: Block applications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Routine general anesthesia protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Routine general anesthesia protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: patient-controlled analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: patient-controlled analgesia
Study: NCT01806506

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy (LSG) is a restrictive bariatric procedure. LSG involves resection of a large part of the body and fundus of the stomach starting from the antrum up to the angle of His. The remaining part of the stomach (the gastric sleeve) is calibrated with a 36 French bougie.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass
Description: Roux-en-Y gastric bypass (RYGB) is an intermediate (restrictive and malabsorptive) operation. RYGB involves creation of a 15-20 mL gastric pouch that is anastomosed to a 100cm Roux limb created at 100cm from the ligament of Treitz.
Study: NCT01453452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: 150 min/wk of moderate exercise through use of the Curves® centers, engage in physical activity outside of Curves®, and use pedometers to track activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: 14 40-min behavioral counseling sessions via telephone with the goal of increasing intervention adherence and increasing participant retention.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: PROMIS-43 - online questionnaire to assess quality of life.
Study: NCT04221503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib (\[3S\]-3-\[4-{7-(aminocarbonyl)-2H-indazol-2-yl} phenyl\] piperidine \[tosylate monohydrate salt\]) is an orally available, potent, highly selective poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP) -1 and -2 inhibitor. The niraparib drug product is provided as 100-mg capsules filled with a dry blend of niraparib tosylate monohydrate, lactose monohydrate, and magnesium stearate in a hard gelatin capsule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niraparib
Description: Niraparib (\[3S\]-3-\[4-{7-(aminocarbonyl)-2H-indazol-2-yl} phenyl\] piperidine \[tosylate monohydrate salt\]) is an orally available, potent, highly selective poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP) -1 and -2 inhibitor. The niraparib drug product is provided as 100-mg capsules filled with a dry blend of niraparib tosylate monohydrate, lactose monohydrate, and magnesium stearate in a hard gelatin capsule.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune
Description: Optune, which is manufactured by Novocure, is a portable battery or power supply operated device which produces alternating electrical fields, called tumor treatment fields (TTFields) within the human body. TTFields are applied to the patient by electrically-insulated surface transducer arrays. TTFields disrupt the rapid cell division exhibited by cancer cells.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optune
Description: Optune, which is manufactured by Novocure, is a portable battery or power supply operated device which produces alternating electrical fields, called tumor treatment fields (TTFields) within the human body. TTFields are applied to the patient by electrically-insulated surface transducer arrays. TTFields disrupt the rapid cell division exhibited by cancer cells.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Planned surgical resection
Description: Surgery of supratentorial glioblastoma (GBM).
Study: NCT04164433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral HIV Self-Test (OraQuick)
Description: The oral HIV self-test is a device for taking a test which is painless. The user gently swipes the test swab along the upper gums once and the lower gums once. The swab is then inserted inside the test tube provided and results are ready in 20 minutes.
Study: NCT01766297

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiotherapy
Study: NCT01823107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Meso BioMatrix Device
Study: NCT02507661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: no-preservation of alveolar ridge - 2 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preservation of alveolar ridge with beta tricalcium phosphate + collagen - 4 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: no-preservation of alveolar ridge - 4 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preservation of alveolar ridge with beta tricalcium phosphate + collagen - 9 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: no-preservation of alveolar ridge - 9 months
Study: NCT00129090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOEP 14 with 12x Rituximab
Description: after amendment 3 patients receive 4x 375mg/m2 in cycle 1 (day 0,1,4,8), 2x 375/m2 in cycle 2 (day1,8) and 1x 375mg/m2 cycle 3-8 (day 1 of each cycle)
Study: NCT04091932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Monthly usage of Pembrolizumab (2mg/kg weight) for 3 months.
Study: NCT01325051

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Raltegravir
Description: 400 mg tablets by mouth BID from Day 1 - Day 7 after enrollment visit
Study: NCT01626586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Therapy
Description: Self-management Diabetes Protocol: Successful adjustment to daily diabetes management requires a wealth of clinical knowledge, solid problem-solving and coping skills to deal with the physical, social and emotional factors associated with caring for and living with a chronic illness, and motivation to take care of one's health.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Therapy
Description: Self-management Diabetes Protocol: Successful adjustment to daily diabetes management requires a wealth of clinical knowledge, solid problem-solving and coping skills to deal with the physical, social and emotional factors associated with caring for and living with a chronic illness, and motivation to take care of one's health.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Therapy
Description: Self-management Diabetes Protocol: Successful adjustment to daily diabetes management requires a wealth of clinical knowledge, solid problem-solving and coping skills to deal with the physical, social and emotional factors associated with caring for and living with a chronic illness, and motivation to take care of one's health.